Brian Cheek

Having fun navigating through Digital Transformation with amazing brand partners

[James - Slack Capital @Slack_Capital]

While @exozymes’ NCT and cannabinoid-like programs are likely to become standalone multi-billion dollar opportunities, their commercial launch ultimately serves a greater purpose... validating the company's cell-free biomanufacturing platform

This is just the first turn of eXoZymes’ flywheel engine!

Most biotech companies are built around a single asset, where success or failure depends on a binary outcome. @eXoZymes is different... the company is designed to repeatedly create, validate and scale high-value compounds across nutraceuticals, pharmaceuticals and beyond

eXoZymes' flywheel works like this:
→ Each compound validates the platform's capabilities
→ Validation attracts partners and licensing deals
→ Each new deal expands the revenue base
→ Revenue accelerates future compound launches

Already, @eXoZymes has 30+ high-impact compounds in its pipeline and is seeing growing interest from pharmaceutical partners

With the two initial programs targeting a combined TAM of $200B, these are not isolated opportunities... they represent the first turns of a continuous flywheel, compounding value back to $EXOZ shareholders

[Brian Cheek @cheeker9]

Coming soon NCT by $EXOZ Exozymes to address many of the issues related to mitochondria distruction - previous undruggable compounds are on the way @thegarybrecka

[Gary Brecka @thegarybrecka]

Every cell in your body contains between 1,000 and 2,500 mitochondria.

They produce 90% of your cellular energy. They regulate inflammation, hormone production, and even the aging process itself.

Mitochondrial dysfunction is now linked to virtually every chronic disease: from Alzheimer's to Type 2 diabetes to cancer.

What improves mitochondrial function: cold exposure, heat therapy, high-intensity interval training, red light therapy, CoQ10, B vitamins, and quality sleep.

Your energy levels are a direct reflection of mitochondrial health. Treat them accordingly.

[eXoZymes @eXoZymes]

Case study from @Springwise featuring Damien @Perriman: Unpacking how eXoZymes and Cayman Chemical are rethinking chemical manufacturing.

@eXoZymes takes enzyme pathways from biology and brings them into the world of chemistry. @CaymanChemical is helping to scale this novel approach

Full case study available here:
https://t.co/qnPhYB8TEw $EXOZ

[James - Slack Capital @Slack_Capital]

Come join the community lead @eXoZymes Investor Discord! 🧬 $EXOZ

https://t.co/A8AIfcvoMg

One of the best places to connect with other shareholders and stay up to date with all the company's developments

[Brian Cheek @cheeker9]

NCT, although very well known for its metabolic benefits, until now has not been able to be produced at scale and purity @CaseyMeansMD @hubermanlab @drmarkhyman @PeterAttiaMD

[eXoZymes @eXoZymes]

Grow Everything podcast: In this episode, Damien Perriman, CCO of @eXoZymes and the commercial lead behind the NCTx spinout, breaks down why cell-free biomanufacturing changes the rules for scaling nature’s rare molecules.

@Perriman states: “eXoZymes is building a disciplined model for bridging invention and market delivery. We remain focused on creating better ways to make important molecules, while vehicles like NCTx are designed to take those opportunities into the market with speed and purpose. When our process performs successfully in someone else’s hands at scale, it reinforces that cell-free biomanufacturing can be a practical commercial platform.”

Full @messaginglab podcast episode available as both video and audio here:
https://t.co/ToVC42CtLa

#exozymes #cellfree #biomanufacturing $EXOZ

[eXoZymes @eXoZymes]

Did you hear @erumazeez's excellent question to @Perriman: "Okay, so if NCT were a superhero, what would its superpower be?"

Hint: It's not your usual superhero... check out the answer in the video below!

The entire podcast episode is definitely worth a listen if you care about where biotech - and biomanufacturing - are actually heading:
https://t.co/ToVC42CtLa

$EXOZ #exozymes #exozyme #enzymes #enzyme #biomanufacturing #biotech #synbio

[James - Slack Capital @Slack_Capital]

Looking forward to @eXoZymes NCTx's Human Use Studies this QUARTER & their Pharmaceutical Analogues preclinical program in H2 2026

If the science proves out, the opportunity here is massive. 1.4+ billion people worldwide are affected by obesity, diabetes & metabolic dysfunction

[James - Slack Capital @Slack_Capital]

@eXoZymes is a value generation flywheel, launching multiple high-value biotech verticals, one spin-out at a time

NCT and Cannabinoids alone represent a $200B TAM and each new vertical stacks permanent, compounding value onto $EXOZ

@eXoZymes is a true biotech powerhouse

[James - Slack Capital @Slack_Capital]

The shift in @eXoZymes underlying narrative is undeniable... the technology is delivering unprecedented results and the commercial opportunity is becoming impossible to ignore

An incredibly exciting period ahead for the company, investors and the future of biomanufacturing!

[eXoZymes @eXoZymes]

In a recent episode of The Big Skinny - the SportsCenter of Financial News - @FoxBusiness contributor, @LouBasenese, stated:

"@eXoZymes is a new way to create chemicals. It's like the @BASF of the 2026 [...] We don't make a lot of the products you buy. We make a lot of the products you buy better."

Full episode available here:
https://t.co/3nCv7DuaOo

#exozymes #exozyme #enzymes #enzyme #biomanufacturing $EXOZ

[James - Slack Capital @Slack_Capital]

A must watch for those interested in @eXoZymes!

Three of the company’s heavy hitters sit down and discuss the events of 2025 as well as the MASSIVE opportunities in 2026 and beyond

[Michael Heltzen @heltzen]

It's time for another Heltzen's Video Highlight: 2025 in Review and Looking Ahead! In this video, I'm having conversations with our CSO, Tyler, and our CCO, Damien, about what happened last year and what we anticipate happening this year.

Full video available here:
https://t.co/9QPRlE5QSr

[James - Slack Capital @Slack_Capital]

@eXoZymes announces a major de-risking event for its NCT compound 🎯📈

The successful pilot-plant demonstration of 100x scale-up and >99% conversion yield confirms the path to unlocking NCT's multi-billion dollar market opportunity towards the end of 2026 $EXOZ

[James - Slack Capital @Slack_Capital]

We've set up a new Discord server for @eXoZymes $EXOZ investors! Come join the future of biomanufacturing👇

https://t.co/yCOmf6xixv

[eXoZymes @eXoZymes]

We're super excited to announce the successful achievement of a 100-fold scale-up of our NCT production process! Producing this externally with @CaymanChemical, we even managed a conversion level of over 99% from feedstock to product! This marks a major milestone in the scalability of our exozymes platform.

Michael @heltzen, CEO of @eXoZymes, “We’re very enthusiastic about this progress and see it as an important inflection point in demonstrating that cell-free, enzyme-driven systems can be engineered to operate reliably at scale. This truly opens the door to producing molecules that have historically been constrained by traditional manufacturing approaches.”

Full story here:
https://t.co/nOI2B47OvC

#exozymes #exozyme #enzymes #enzyme #biomanufacturing #NCT $EXOZ

[eXoZymes @eXoZymes]

"There are moments in science when something small and elusive suddenly becomes attainable, when a molecule trapped in the fine print of research papers becomes the centerpiece of an entirely new chapter in health. That is what happened when eXoZymes turned its attention to plant-derived N-trans-caffeoyltyramine (NCT), an investigational compound with the potential to change how the world treats chronic metabolic and inflammatory diseases."

“The beauty of leading with NCT,” said Damien Perriman (@Perriman), eXoZymes’ Chief Commercial Officer, “is that we’ve taken something nature only whispers about and figured out how to make it into something we can actually use, because we can provide it at scale.”

Full @VanityFair article available here:
https://t.co/2oLIvEUsjA

#exozymes #exozyme #enzymes #enzyme #nct #nctx #biomanufacturing #biosolutions

[Lou Basenese @LouBasenese]

🚀 In Episode #2 of The Upside we discuss…

How $EXOZ is using AI to create enzymes for sustainable chemical production.

This is biomanufacturing without cells – faster, cleaner, smarter.

No jargon. No gatekeepers. Just direct access to CEO Michael Heltzen – and the upside behind eXoZyme’s innovation.

[Brian Cheek @cheeker9]

@marklevinshow How many games in mlb season

[Brian Cheek @cheeker9]

@CurationMostly @StartupArchive_ $EXOZ

[Brian Cheek @cheeker9]

@meelonmuskusa HOPE